Asia Pacific Newborn Screening Market

The Asia Pacific newborn screening market was valued at US$ 270.13 million in 2022 and is expected to reach US$ 602.14 million by 2030; it is estimated to grow at a CAGR of 10.5% from 2022 to 2030.

Genetic Screening of Newborns Fuels the Asia Pacific Newborn Screening Market.

The demand for comprehensive genetic screening of newborns is rising with the deepening knowledge about the genetic causes of medical conditions and advancements in healthcare technologies. As a result, companies in the newborn screening market are developing innovative, cost-effective screening solutions. Yescarta and Zynteglo are two more examples of authorized gene treatments for large B-cell lymphoma and beta-thalassemia. Further, the emergence of technologies conferring an ability to identify genetic predispositions to diseases at birth pave the way for personalized healthcare, aligning with the broader trend of precision medicine.

Screening for genetic diseases during pregnancy also focuses on the early detection of pregnancy-related problems. Next-generation sequencing aids in the prenatal screening of neonates with a sensitivity of above 95% for detecting aneuploidies (such as Down syndrome and Trisomy 21) or partial chromosomal abnormalities (duplications or deletions) in all chromosomes. Fluorescence in-situ hybridization (FISH) is employed to detect monogenic illnesses such as sickle cell anemia; it also aids in an effective preimplantation genetic diagnosis. Noninvasive procedures such as the cell-free fetal DNA approach using maternal plasma are the recent advancements in genetic tests. The embryonic DNA can be distinguished from maternal DNA pieces based on differences in their sizes. Real-time PCR with fluorescent probes, shotgun sequencing (Solexa or Illumina), or huge targeted parallel sequencing can be used to examine DNA associated with fetal medical conditions. This would allow doctors to provide early molecular interventions with certain pharmacological therapies (pharmacogenetics) and to transform cells, tissues, and organs physically and chemically if this type of genetic screening is further researched. Thus, advancements in methods for screening infants for genetic disorders hold immense potential for the overall newborn screening market.

Asia Pacific Newborn Screening Market Overview

The newborn screening market in Asia Pacific is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The Asia -Pacific newborn screening market is segmented into Japan, China, India, South Korea, Australia, and the Rest of Asia -Pacific. Asia -Pacific is expected to be the fastest-growing region in the global newborn screening market during 2022-2030. The projected growth of the market in this region can be associated with the high number of newborn births, the soaring prevalence of congenital diseases, rising awareness regarding early diagnosis of birth defects in newborns, and the presence of organizations working toward offering better solutions for newborn screening.

Screening of newborns in Asia -Pacific is gaining traction; government agencies in China, India, and other countries need to implement newborn screening programs owing to the high birth rate. According to the United Nations International Children's Emergency Fund (UNICEF), 67,385 babies are born in India each day, accounting for one-sixth of childbirths recorded globally in a day. In addition, India has become the most populated nation; as per Worldmapper, ~23 million babies were born in 2022, followed by China with the birth of 10 million babies. With the constantly soaring birth rate, the focus on infant care is increasing in India, as well as in other countries in Asia -Pacific.

Asia Pacific Newborn Screening Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Newborn Screening Market Segmentation 

The Asia Pacific newborn screening market is segmented based on product type, technology, test type, end user, and country.

Based on product type, the Asia Pacific newborn screening market is bifurcated into reagents and assay kits, and instruments. The reagents and assay kits segment held a larger Asia Pacific newborn screening market share in 2022. The reagents and assay kits segment is subsegmented into DNA-based assays, and immunoassays and enzymatic assays. Instruments segment is subsegmented into newborn disorder screening instruments, pulse oximeters, newborn hearing screening instruments, and other instruments.

In terms of technology, the Asia Pacific newborn screening market is categorized into tandem mass spectrometry (TMS), molecular assays, immunoassays and enzymatic assay, pulse oximetry screening technology, and other technologies. The pulse oximetry screening technology segment held the largest Asia Pacific newborn screening market share in 2022.

Based on test type, the Asia Pacific newborn screening market is categorized into dry blood spot test, hearing screen test, critical congenital heart diseases (CCHD) test, and other test types. The dry blood spot test segment held the largest Asia Pacific newborn screening market share in 2022.

By end user, the Asia Pacific newborn screening market is segmented into hospitals and clinics and diagnostic laboratories. The hospitals and clinics segment held a larger Asia Pacific newborn screening market share in 2022. 

Based on country, the Asia Pacific newborn screening market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific newborn screening market in 2022.

Bio-Rad Laboratories Inc, LifeCell International Pvt Ltd, Masimo Corp, Medtronic Plc, Natus Medical Inc, PerkinElmer Inc, Trivitron Healthcare Pvt Ltd, and Waters Corp are some of the leading companies operating in the Asia Pacific newborn screening market.

Asia Pacific Newborn Screening Strategic Insights

Strategic insights for the Asia Pacific Newborn Screening provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Newborn Screening Report Scope

Asia Pacific Newborn Screening Regional Insights

The geographic scope of the Asia Pacific Newborn Screening refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.